Ron Akehurst

3.5k total citations
79 papers, 2.5k citations indexed

About

Ron Akehurst is a scholar working on Economics and Econometrics, General Health Professions and Psychiatry and Mental health. According to data from OpenAlex, Ron Akehurst has authored 79 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Economics and Econometrics, 16 papers in General Health Professions and 8 papers in Psychiatry and Mental health. Recurrent topics in Ron Akehurst's work include Health Systems, Economic Evaluations, Quality of Life (30 papers), Healthcare cost, quality, practices (10 papers) and Healthcare Policy and Management (10 papers). Ron Akehurst is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (30 papers), Healthcare cost, quality, practices (10 papers) and Healthcare Policy and Management (10 papers). Ron Akehurst collaborates with scholars based in United Kingdom, United States and Canada. Ron Akehurst's co-authors include John Brazier, Alan Brennan, Karl Claxton, Mark Sculpher, Andrew Briggs, Martin Buxton, Chris McCabe, Matt Stevenson, Katy Cooper and Jason Madan and has published in prestigious journals such as The Lancet, Gastroenterology and Environmental Health Perspectives.

In The Last Decade

Ron Akehurst

75 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron Akehurst United Kingdom 23 905 424 344 305 261 79 2.5k
Ataru Igarashi Japan 25 669 0.7× 631 1.5× 221 0.6× 197 0.6× 361 1.4× 197 2.7k
David Wonderling United Kingdom 25 724 0.8× 385 0.9× 359 1.0× 217 0.7× 753 2.9× 47 3.1k
Ruth E. Brown Canada 35 851 0.9× 433 1.0× 242 0.7× 266 0.9× 508 1.9× 109 3.7k
Anita Chawla United States 20 510 0.6× 377 0.9× 221 0.6× 261 0.9× 250 1.0× 47 2.2k
T Walley United Kingdom 31 761 0.8× 569 1.3× 161 0.5× 215 0.7× 387 1.5× 82 3.0k
A Fry-Smith United Kingdom 32 445 0.5× 363 0.9× 154 0.4× 179 0.6× 318 1.2× 48 3.9k
Kiichiro Tsutani Japan 25 482 0.5× 205 0.5× 288 0.8× 123 0.4× 213 0.8× 125 2.6k
Kathryn Fitch United States 16 555 0.6× 566 1.3× 322 0.9× 139 0.5× 327 1.3× 33 2.6k
Eldon Spackman Canada 26 746 0.8× 578 1.4× 141 0.4× 295 1.0× 193 0.7× 102 2.7k
Dorte Ejg Jarbøl Denmark 25 378 0.4× 430 1.0× 263 0.8× 180 0.6× 640 2.5× 147 2.4k

Countries citing papers authored by Ron Akehurst

Since Specialization
Citations

This map shows the geographic impact of Ron Akehurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Akehurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Akehurst more than expected).

Fields of papers citing papers by Ron Akehurst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Akehurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Akehurst. The network helps show where Ron Akehurst may publish in the future.

Co-authorship network of co-authors of Ron Akehurst

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Akehurst. A scholar is included among the top collaborators of Ron Akehurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Akehurst. Ron Akehurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kruzikas, Denise, et al.. (2020). HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications. Journal of Managed Care & Specialty Pharmacy. 26(12). 1548–1557. 2 indexed citations
2.
Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2018). A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics. 36(5). 603–612. 7 indexed citations
3.
4.
5.
Nadipelli, Vijay R., et al.. (2016). Health-Related Quality of Life in Opioid use Disorder Measured by Utilities: A Systematic Literature Review. Value in Health. 19(7). A387–A387. 1 indexed citations
6.
Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2016). Assessing The Cost-Utility of Etelcalcetide: A Markov Model. Value in Health. 19(7). A519–A519. 2 indexed citations
7.
Rycroft, Catherine, et al.. (2015). The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain Studies. Value in Health. 18(8). 987–993. 3 indexed citations
8.
Morgan, Gareth J., Antonio Palumbo, Sujith Dhanasiri, et al.. (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology. 168(6). 820–823. 14 indexed citations
9.
Latimer, Nicholas, Keith R. Abrams, Paul C. Lambert, et al.. (2013). A Guide to Adjusting Survival Time Estimates to Account for Treatment Switching in Randomised Controlled Trials. Value in Health. 16(7). A325–A325. 22 indexed citations
10.
Skedgel, Chris, Allan Wailoo, & Ron Akehurst. (2013). Choosing vs. allocating: discrete choice experiments and constant‐sum paired comparisons for the elicitation of societal preferences. Health Expectations. 18(5). 1227–1240. 34 indexed citations
11.
Park, Haesuk, Karen L. Rascati, Michael W. Keith, et al.. (2011). Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value in Health. 14(8). 1002–1009. 24 indexed citations
12.
Lloyd, Andrew, Paul Hodgkins, Rahul Sasané, et al.. (2011). Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations. Patient. 4(4). 247–257. 16 indexed citations
13.
Bodger, Keith, et al.. (2010). A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics. 13(1). 148–161. 21 indexed citations
14.
Stevenson, Matt, et al.. (2009). The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III. Value in Health. 12(8). 1100–1105. 13 indexed citations
15.
Kaltenthaler, Eva, Paul Tappenden, Andrew Booth, & Ron Akehurst. (2008). Comparing methods for full versus single technology appraisal: A case study of docetaxel and paclitaxel for early breast cancer. Health Policy. 87(3). 389–400. 8 indexed citations
16.
Claxton, Karl, Mark Sculpher, Anthony J. Culyer, et al.. (2005). Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion. Health Economics. 15(1). 1–4. 67 indexed citations
17.
Allain, J P, et al.. (1999). Autologous transfusion, 3 years on: What is new? What has happened?. Transfusion. 39(8). 910–911. 9 indexed citations
18.
McCabe, Christopher & Ron Akehurst. (1997). 9 Health economics in rheumatology. Baillière s Clinical Rheumatology. 11(1). 145–156. 4 indexed citations
19.
Akehurst, Ron, et al.. (1993). Cost-effectiveness in dental health: a review of strategies available for preventing caries. RePEc: Research Papers in Economics. 7 indexed citations
20.
Akehurst, Ron, et al.. (1978). Application of Cost–Benefit Analysis to Programmes for the Prevention of Mental Handicap. Novartis Foundation symposium. 173–191. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ataru Igarashi Breakdown of academic impact, for papers by David Wonderling Breakdown of academic impact, for papers by Ruth E. Brown Breakdown of academic impact, for papers by Anita Chawla Breakdown of academic impact, for papers by T Walley Breakdown of academic impact, for papers by A Fry-Smith Breakdown of academic impact, for papers by Kiichiro Tsutani Breakdown of academic impact, for papers by Kathryn Fitch Breakdown of academic impact, for papers by Eldon Spackman Breakdown of academic impact, for papers by Dorte Ejg Jarbøl
Rankless by CCL
2026